Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

Benzinga · 2d ago
Citigroup analyst Daniel Grosslight maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from $300 to $330.